Literature DB >> 15857294

Colloidal carriers for ophthalmic drug delivery.

Rubiana Mara Mainardes1, Maria Cristina Cocenza Urban, Priscila Oliveira Cinto, Najeh Maissar Khalil, Marco Vinícius Chaud, Raul Cesar Evangelista, Maria Palmira Daflon Gremiao.   

Abstract

To achieve effective drug concentration at the intended site for a sufficient period of time is a requisite desired for many drug formulations. For drugs intended to ocular delivery, its poor bioavailability is due to pre-corneal factors. Most ocular diseases are treated by topical drug application in the form of solution, suspension and ointment. However, such dosage forms are no longer sufficient to combat some ocular diseases. Intravitreal drug injection is the current therapy for disorders in posterior segment. The procedure is associated with a high risk of complications, particularly when frequent, repeated injections are required. Thus, sustained-release technologies are being proposed, and the benefits of using colloidal carriers in intravitreal injections are currently under investigation for posterior drug delivery. This review will discuss recent progress and specific development issues relating to colloidal drug delivery systems, such as liposomes, niosomes, nanoparticles, and microemulsions in ocular drug delivery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857294     DOI: 10.2174/1389450053765914

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  26 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

Review 2.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 3.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

4.  Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Soumyajit Majumdar
Journal:  Eur J Pharm Biopharm       Date:  2016-10-25       Impact factor: 5.571

5.  Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits.

Authors:  David J Miller; S Kevin Li; Anthony L Tuitupou; Rajan P Kochambilli; Kongnara Papangkorn; Donald C Mix; William I Higuchi; John W Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

Review 6.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

7.  Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Authors:  Hussein O Ammar; H A Salama; M Ghorab; A A Mahmoud
Journal:  AAPS PharmSciTech       Date:  2009-06-18       Impact factor: 3.246

8.  Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration.

Authors:  Bing Liu; Li Ding; Xiaowen Xu; Hongda Lin; Chenglong Sun; Linjun You
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-17       Impact factor: 2.441

9.  Alginate microsphere-collagen composite hydrogel for ocular drug delivery and implantation.

Authors:  Wenguang Liu; May Griffith; Fengfu Li
Journal:  J Mater Sci Mater Med       Date:  2008-06-11       Impact factor: 3.896

Review 10.  Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications.

Authors:  Blake A Booth; Lori Vidal Denham; Saadallah Bouhanik; Jean T Jacob; James M Hill
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.